Successful management of camrelizumab-induced immune-checkpoint-inhibitors-related myocarditis.

Long, Hui-Dong; Du, Yi-Peng; Wang, Li-Yan; Liu, Guan-Cheng; Liang, Shi-Xiang; Zeng, Zhao-Hua; Lin, Yun-En

Long, Hui-Dong; Du, Yi-Peng; Wang, Li-Yan; Liu, Guan-Cheng; Liang, Shi-Xiang; Zeng, Zhao-Hua; Lin, Yun-En.

Afiliación

Long HD; Department of Medical Oncology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China.
Du YP; Department of Cardiology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Wang LY; Department of Urology Oncology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China.
Liu GC; Department of Ultrasound Room, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China.
Liang SX; Department of Medical Oncology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China.
Zeng ZH; Department of Cardiology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Lin YE; Department of Pathology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China.

J Oncol Pharm Pract ; : 10781552231216104, 2023 Dec 03.

Article en En | MEDLINE | ID: mdl-38043937

Palabras clave

Immune checkpoint inhibitor; case report; immunotherapy-related adverse reactions; myocarditis; toxicity

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: J Oncol Pharm Pract Asunto de la revista: FARMACIA Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google